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Abstract
Objective To assess the relation between troponin concentration, assay
precision, and clinical outcomes in patients with suspected acute
coronary syndrome.
Design Cohort study.
Setting Tertiary centre in Scotland.
Participants 2092 consecutive patients admitted with suspected acute
coronary syndrome were stratified with a sensitive troponin I assay into
three groups (<0.012, 0.012-0.049, and ≥0.050 µg/L) based on the 99th
centile for troponin concentration (0.012 µg/L; coefficient of variation
20.8%) and the diagnostic threshold (0.050 µg/L; 7.2%).
Main outcome measure One year survival without events (recurrent
myocardial infarction, death) in patients grouped by troponin
concentration.
Results Troponin I concentrations were <0.012 µg/L in 988 patients
(47%), 0.012-0.049 µg/L in 352 patients (17%), and ≥0.050 µg/L in 752
patients (36%). Adoption of the 99th centile would increase the number
of people receiving a diagnosis of myocardial infarction from 752 to 1104:
a relative increase of 47%. At one year, patients with troponin
concentrations of 0.012-0.049 µg/L were more likely to be dead or
readmitted with recurrent myocardial infarction than those with troponin
concentrations <0.012 µg/L (13% v 3%, P<0.001; odds ratio 4.7, 95%
confidence interval 2.9 to 7.9). Compared with troponin ≥0.050 µg/L,
patients with troponin 0.012-0.049 µg/L had a higher risk profile but were
less likely to have a diagnosis of, or be investigated and treated for,
acute coronary syndrome.
Conclusion Lowering the diagnostic threshold to the 99th centile and
accepting greater assay imprecision would identify more patients with
acute coronary syndrome at risk of recurrent myocardial infarction and
death but would increase the diagnosis of myocardial infarction by 47%.
It remains to be established whether reclassification of these patients
and treatment for myocardial infarction would improve outcome.
Introduction
The consensus statement on the universal definition of
myocardial infarction recommends that an increase in plasma
troponin concentration above the 99th centile of a normal
reference population is used to confirm the diagnosis.1 Despite
this guidance, lowering the diagnostic threshold for troponin
remains a highly contentious issue, with clinicians uncertain as
to whether the benefits of improved sensitivity will outweigh
problems that might arise from reduced specificity.2
The Global Task Force for the Universal Definition of
Myocardial Infarction1 and the National Academy of Clinical
Biochemistry3 recommend the 99th centile as the diagnostic
threshold where assay precision can be shownwith a coefficient
of variation of ≤10% at this concentration. Currently few assays
are able to meet these precision criteria at the diagnostic
threshold and nearly all institutions therefore select a diagnostic
threshold above the 99th centile where the coefficient of
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variation is ≤10% to minimise the risk of false positive results
and an inappropriate diagnosis of myocardial infarction. We
recently showed that the introduction of a sensitive troponin I
assay halved the rate of recurrent myocardial infarction and
death in patients presenting with suspected acute coronary
syndrome and a small increase in plasma troponin
concentration.4 Despite improved sensitivity, this assay did not
have the recommended level of precision at the 99th centile of
0.012 µg/L.We therefore reduced the threshold from 0.200 µg/L
to 0.050 µg/L, the lowest concentration at which the coefficient
of variation was ≤10%, for the clinical diagnosis of myocardial
infarction.
A recent statement from the Biochemistry Group of the Global
Task Force for the Universal Definition ofMyocardial Infarction
represents a change in position, with the recommendation that
the 99th centile be adopted as the diagnostic threshold for current
sensitive troponin assays irrespective of whether the coefficient
of variation is less than 10% at this concentration.5 This
recommendation is based in part on modelling exercises that
suggest assays with imprecision of up to 20% do not affect
diagnostic accuracy.6 To determine the potential impact of this
change in guidance on clinical practice, we evaluated the relation
between plasma troponin concentration, assay precision, and
clinical outcomes in our previous cohort of consecutive patients
admitted to hospital with suspected acute coronary syndrome.4
Methods
Study population
We identified consecutive patients admitted with suspected
acute coronary syndrome to the Royal Infirmary, Edinburgh,
United Kingdom, during the validation (from 1 February 2008
to 31 July 2008) and implementation (from 1 February 2009 to
31 July 2009) of a sensitive troponin I assay.4
Inclusion criteria were symptoms of chest pain of suspected
cardiac origin and measurement of plasma troponin I
concentrations on admission or 12 hours after the onset of
symptoms, or both. Exclusion criteria were non-cardiac
(respiratory, gastrointestinal, or musculoskeletal) chest pain,
tachyarrhythmia, anaemia (haemoglobin concentration <900
g/L), severe valvular heart disease, hypertrophic
cardiomyopathy, pericarditis, cocaine use, or patients who were
non-resident.
Information on patients and clinical outcomes were obtained
through the TrakCare software application (InterSystems
Corporation, Cambridge,MA, US), an electronic patient record
system used by the Acute Hospitals Division of Lothian National
Health Service Health Board, Scotland.
Troponin assay
Plasma troponin I concentrations weremeasured with the Abbott
ARCHITECT troponin I assay (Abbott Laboratories, Abbott
Park, IL, US). This assay was reformulated by the manufacturer
to achieve a greater analytical sensitivity of ≤0.01 µg/L where
the 99 centile of a reference population (men and women) was
reported to be 0.012 µg/L. We previously determined the
interassay coefficient of variation across a wide range of plasma
troponin concentrations and established that the reformulated
assay showed a coefficient of variation of <10% at 0.050 µg/L
under local laboratory conditions.4 As recommended in the
consensus statement on the universal definition of myocardial
infarction, this was selected as the diagnostic threshold for
clinical use. Patients were stratified into three groups based on
the 99th centile for plasma troponin (0.012 µg/L) and the
diagnostic threshold of 0.050 µg/L: <0.012 µg/L, 0.012-0.049
µg/L, and ≥0.050 µg/L.
A further evaluation of assay precision at low concentrations
of troponin (<0.050 µg/L) was carried out by using donor plasma
with undetectable troponin I (base pool) spiked with control
material to achieve concentrations between 0.010 µg/L and
0.050 µg/L. The coefficient of variation was established in 10
replicates on two separate occasions at each concentration.
Clinical characteristics and outcome
Clinical characteristics, cardiovascular risk factors, and drugs
taken on admission were documented. Hyperlipidaemia and
hypertension were defined as either a documented history or
the use of a lipid lowering or antihypertensive drug, respectively.
Thrombolysis in myocardial infarction (TIMI) risk scores were
calculated and the presence of any electrocardiographic changes
were recorded. Management during the index admission was
assessed, including referral to specialist cardiology services,
coronary angiography, coronary revascularisation, and use of
medical treatments.
Subsequent readmission with myocardial infarction or death
from any cause was recorded.Myocardial infarction was defined
according to international guidelines where there was evidence
of myocardial necrosis by using plasma troponin concentration
of ≥0.050 µg/L as the diagnostic threshold in a clinical setting
consistent with myocardial ischemia.1
Statistical analysis
We compared continuous variables with analysis of variance
and categorical variables with χ2 test or exact methods where
the expected values were small across groups. Event-free
survival (reinfarction and death) was compared with
Kaplan-Maier survival curves and log rank tests.
We used logistic regression adjusted for potential confounders
to model the association between troponin concentration and
event-free survival at 12 months. Missing data were uncommon
for variables included in the regression model (0-7.5% missing
data) and therefore complete case analysis was performed with
95 patients excluded from the analysis because of missing data
for covariates. In sensitivity analyses, we analysed time to death
or recurrent myocardial infarction in Cox proportional hazards
models. We examined the linearity of the association between
troponin concentration and odds of death or recurrent myocardial
infarction using generalised additivemodels. Data were analysed
with SAS version 9 (SAS Institute, Cary, NC, US), GraphPad
Prism (GraphPad, La Jolla, CA, US), and R 211.1 (Vienna,
Austria).
Results
We identified 3434 patients who met the inclusion criteria, of
whom 1342 had one or more of the prespecified exclusion
criteria, resulting in a final study population of 2092 patients
with suspected acute coronary syndrome.Within this population,
troponin concentrations were <0.012 µg/L in 988 (47%),
0.012-0.049 µg/L in 352 (17%), and ≥0.050 µg/L in 752 (36%)
patients.
Adoption of the 99th centile as the diagnostic threshold would
increase the number of patients with a diagnosis of myocardial
infarction from 36% (752/2092) to 53% (1104/2092), a relative
increase of 47%.
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Clinical characteristics
Patients with troponin concentrations 0.012-0.049 µg/L were
older and more likely to have a history of ischaemic heart
disease, previous revascularisation, stroke, hypertension, and
hyperlipidaemia than those who had concentrations <0.012 µg/L
(table 1⇓). They were also more likely to have an abnormal
result on 12 lead electrocardiography (ST segment depression,
T wave inversion, or bundle branch block) and renal impairment
and to already be established on cardiac drugs than patients with
troponin concentrations <0.012 µg/L.
Patients with troponin concentrations 0.012-0.049 µg/L were a
similar age to the patients with troponin concentrations ≥0.050
µg/L, although they were more likely to have a history of
ischaemic heart disease and coronary revascularisation and to
be established on cardiac drugs before admission (P<0.05 for
all). There were no differences in renal function between these
groups of patients, but those with concentrations 0.012-0.049
µg/L were more likely to present with T wave inversion or
bundle branch block on the 12 lead electrocardiogram and less
likely to have ST segment depression or elevation.
Management during index admission
Rates of referral to cardiology and for coronary revascularisation
did not differ between patients with troponin concentrations
<0.012 µg/L and 0.012-0.049 µg/L. Compared with those with
troponin concentrations ≥0.050 µg/L, patients with troponin
concentrations of 0.012-0.049 µg/L were less likely to be
diagnosed with unstable angina or an acute coronary syndrome
(98/352 (28%) v 692/752 (92%)), referred to a cardiologist
(129/352 (37%) v 642/752 (85%)), receive dual antiplatelet
treatment (46/352 (13%) v 550/752 (73%)), or undergo coronary
revascularisation (16/352 (5%) v 394/752 (52%)) (P<0.001 for
all) (table 2⇓).
Clinical outcomes
Patients were followed up for a median of 446 (range 366-572)
days. At 12 months, patients with troponin concentrations of
0.012-0.049 µg/L were four times more likely to have died or
been readmitted with recurrent myocardial infarction than those
with troponin concentrations <0.012 µg/L (47/352 (13%) v
31/988 (3%), P<0.001, odds ratio 4.7, 95% confidence interval
2.9 to 7.9; table 3⇓ and fig 1⇓). Differences in outcome were
already apparent at three months, with 19/352 (5%) patients
with troponin concentration 0.012-0.049 µg/L dead or readmitted
with a myocardial infarction compared with 13/988 (1%) of
patients with troponin concentration <0.012 µg/L (P<0.001,
odds ratio 4.6, 2.5 to 8.5).
After adjustment for age, sex, history of vascular disease,
diabetes mellitus, hypertension, and hyperlipidaemia, troponin
concentration 0.012-0.049 µg/L predicted death or recurrent
myocardial infarction at 12 months with an adjusted odds ratio
of 2.5 (1.5 to 4.3) compared with those with troponin
concentrations <0.012 µg/L (P<0.001). Similar estimates were
obtained in sensitivity analyses with additional adjustment for
smoking status, estimated glomerular filtration rate, and
abnormal results on echocardiography (2.3, 1.3 to 4.1). Hazard
ratios for time to first event obtained in Cox proportional hazards
models were similar to the odds ratios for death or recurrent
myocardial infarction at one year.
The association between troponin and risk of death or recurrent
myocardial infarction was non-linear (P=0.005, fig 2⇓), but
there was no evidence of a threshold at the 10% coefficient of
variation (0.050 µg/L) or the 99th centile (0.012 µg/L). Instead,
risk increased from an undetectable level to concentrations of
about 0.020 µg/L, at which point a threshold was observed above
which risk of death or recurrent myocardial infarction did not
increase further. An increase in the proportion of patients dead
or readmitted with myocardial infarction at one year was
observed with each quarter between 0.012 µg/L and 0.050 µg/L
(fig 3⇓). Clinical outcomes in the lowest quarter (0.012-0.014
µg/L) were similar to those in patients with troponin
concentrations <0.012 µg/L, and outcomes in the highest quarter
(0.026-0.049 µg/L) were similar to those patients with troponin
concentrations ≥0.050 µg/L. The coefficient of variation for
troponin measured within each quarter increased from 7.2% at
the diagnostic threshold of 0.050 µg/L, to 20.8% at the 99th
centile of 0.012 µg/L, to 28.9% at concentrations below the 99th
centile (fig 3⇓).
Despite reductions in the precision of the assay at low
concentrations, plasma troponin concentration remained a good
discriminator for death and recurrent myocardial infarction with
a C statistic (area under the curve) of 0.75 for patients with
troponin concentrations <0.050 µg/L. Lowering the diagnostic
threshold from 0.050 µg/L to 0.012 µg/L increased the negative
predictive value of troponin from 94% to 97%, while the positive
predictive value decreased from 25% to 22% (see appendix
table on bmj.com).
Discussion
In patients with suspected acute coronary syndrome, any
increase in plasma troponin concentration above the 99th centile
of a healthy reference population was associated with recurrent
myocardial infarction or death. Lowering the diagnostic
threshold to the 99th centile and accepting greater assay
imprecision will identify more patients at risk of recurrent events
but would potentially increase the diagnosis of myocardial
infarction by 47%.
Risk stratification
Patients with suspected acute coronary syndrome and increased
troponin concentrations measured with conventional assays are
known to have poorer short and long term clinical outcomes.7-10
These observations were derived from a homogenous group of
high risk selected patients participating in clinical trials. The
definition of a raised troponin concentration differed widely
between these studies, and the prognosis of unselected patients
with small increases in troponin concentration detectable only
with contemporary sensitive troponin assays has not been
assessed and remains uncertain.11
We have shown that unselected patients with suspected acute
coronary syndrome and small increases in troponin concentration
above the 99th centile (0.012 µg/L), but below our diagnostic
threshold based on the 10% coefficient of variation (0.050 µg/L),
were four to five times more likely to die or have a recurrent
myocardial infarct than those with plasma troponin
concentrations below the 99th centile. Although patients with
troponin concentration 0.012-0.049 µg/L were older and more
likely to have established ischaemic heart disease or
cardiovascular risk factors than those patients with a troponin
concentration in the normal reference range, plasma troponin
concentration remained an independent predictor of clinical
outcome even after adjustment for these clinical characteristics.
Our findings are consistent with recent studies of patients with
acute coronary syndrome participating in randomised clinical
trials where troponin concentrations above the 99th centile were
associated with poorer outcomes.12 13 Importantly, our study
population comprised consecutive unselected “real world”
patients admitted with suspected cardiac chest pain rather than
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a homogeneous group of patients with a clinical diagnosis of
acute coronary syndromewhowere receiving optimal treatment.
We currently do not report troponin concentrations below the
diagnostic threshold (0.050 µg/L) for myocardial infarction and
therefore we have yet to realise the full potential for sensitive
troponin assays to improve risk stratification in clinical practice.
Lowering the diagnostic threshold further will identify many
more patients who will go on to have recurrent events. It has
recently been shown that the GRACE score continues to be a
powerful predictor of clinical outcome even with the availability
of high sensitive cardiac troponin assays.14 Troponin, however,
is included as a categorical rather than a continuous variable in
the GRACE score, and therefore the true potential for sensitive
troponin assays to add to current clinical risk prediction tools
requires further evaluation.
Diagnosis of myocardial infarction
Will lowering the diagnostic threshold and reclassification of
patients with suspected acute coronary syndrome as myocardial
infarction alter clinical outcomes? We have previously shown
that lowering the diagnostic threshold from 0.200 µg/L to 0.050
µg/L was associated with a change in clinical practice, with
more referrals to cardiac specialists, more coronary angiography,
and wider use of evidenced based treatments.2 This alteration
in diagnosis and practice was associated with a marked
improvement in clinical outcome with a halving in the rates of
recurrent myocardial infarction and death. In our current study,
patients with troponin concentrations 0.012-0.049 µg/L did not
receive a diagnosis of or were managed for myocardial
infarction, and were less likely to be referred to a cardiologist,
or considered for revascularisation, despite the higher rates of
previous ischaemic heart disease. It remains to be established
whether diagnosis and treatment in these patients with acute
myocardial infarction would also improve clinical outcomes to
a similar extent.
While sensitive troponin assays undoubtedly improve our ability
to rule out acute myocardial infarction,15 16 many clinicians are
concerned that the use of progressively lower diagnostic
thresholds will result in the misdiagnosis of myocardial
infarction and that small increases in troponin concentrations
could be caused by other conditions. This could lead to
inappropriate hospital admissions, misdiagnosis, initiation of
potentially detrimental treatments, and poorer clinical outcomes
for patients. In our study, adoption of the 99th centile as the
diagnostic threshold would potentially result in a 47% increase
in the number of patients with a diagnosis of myocardial
infarction and would have major implications for healthcare
resources, public health targets, and government statistics and
on the employment prospects and insurance policies of our
patients. If a similar increase in the rate of diagnosis were to
occur across the UK, we anticipate the number of patients with
acute myocardial infarction would increase by about 42 000 a
year.17 18 Lowering the diagnostic threshold would also
potentially increase the number of patients referred for inpatient
coronary angiography by 42% and increase the use of secondary
prevention by 8% for statins, 12% for angiotensin converting
enzyme inhibitors, and 30% for clopidogrel. Moreover, the
impact of adopting the 99th centile on healthcare resources is
likely to be underestimated here as we included only patients
with suspected acute coronary syndrome.We identified several
prespecified exclusion criteria to avoid patients with clearly
defined non-cardiac or non-coronary causes of chest pain and
therefore our analysis does not take into account patients with
secondary causes of myocardial ischemia who are likely to
undergo additional investigation.
In our previous study patients with an undisclosed troponin of
0.05-0.19 µg/L had a high event rate of 39% at one year. In
comparison, patients with undisclosed troponin concentrations
of 0.012-0.049 µg/L were at lower risk, with a one year event
rate of 13%. Therefore there might be less to gain from the
reclassification and treatment of these patients for myocardial
infarction. As such we believe it is important to assess whether
this change in practice will translate into improvements in
clinical outcomes. This requires additional prospective studies
across a range of healthcare settings with a formal assessment
of cost effectiveness.
Defining an appropriate diagnostic threshold
The successful design of prospective clinical trials will critically
depend on the selection and determination of the population of
apparently healthy people with which to define the normal
reference range.19 Troponin concentrations in apparently healthy
people differ between men and women,20 increase with age,21
and are even raised in endurance athletes,22 yet current guidance
recommends a single diagnostic threshold. Furthermore, in a
large cohort of patients with stable coronary heart disease and
preserved left ventricular function, plasma troponin
concentrations were above the 99th centile in 11% of patients.23
When we started this study, the manufacturers of the
ARCHITECT STAT troponin I assay defined the 99th centile
as 0.012 µg/L but, after additional studies in apparently healthy
populations, the 99th centile was revised to 0.028 µg/L. The
appropriate population from which to determine the reference
range for patients with suspected acute coronary syndrome has
yet to be determined and perhaps should include patients with
stable coronary artery disease.
When examining the linearity of association between troponin
concentration and death or recurrent myocardial infarction, we
found no evidence of a threshold at the 10% coefficient of
variation or the 99th centile. This is perhaps not surprising given
these levels are based on the limits of assay precision or
assumptions about the normal distribution of troponin in an
unrelated population, respectively. In our population of patients
with suspected acute coronary syndrome, the risk of recurrent
events increased linearly from an undetectable level with a
genuflection and plateau at a troponin concentration of about
0.020 µg/L, above which risk does not seem to increase further.
It is tempting to speculate that this concentration could represent
a more clinically relevant threshold on which to base the
diagnosis of myocardial infarction.
Our data support the need to re-evaluate the level of precision
recommended for the current generation of troponin assays.
While prototype high sensitive troponin I assays24 25 and a
commercially available high sensitive troponin T assay22 can
show less than 10% coefficient of variation at the 99th centile,
most do not.26The Biochemistry Group of the Global Task Force
recently recommended the use of lower diagnostic thresholds,
even though the coefficient of variation might be as high as
20% at the 99th centile.5 This change in position was based
partly on modelling exercises that suggest assays with greater
imprecision of up to 20% coefficient of variation do not affect
diagnostic accuracy.6 Our findings support these
recommendations; using higher diagnostic thresholds to
maximise assay precision will miss a considerable proportion
of patients with suspected acute coronary syndrome at risk of
recurrent events.
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Generalisability
Lowering the diagnostic threshold for myocardial infarction
will have major implications for both specialists and general
physicians working in emergency departments or acute receiving
units in secondary and tertiary care hospitals. While we report
findings from a single tertiary care hospital using a specific
contemporary sensitive troponin I assay and diagnostic
threshold, this issue is not particular to our centre or indeed the
assay. Our study population represents unselected patients who
self present or are referred from primary care practitioners to
our institution. While the troponin concentration at the 99th
centile will differ slightly between assays, the impact of adopting
the 99th centile on the rate of diagnosis of myocardial infarction
will be similar across all assays. Troponin I assays are used in
the diagnosis of myocardial infarction in more than 70% of
clinical laboratories worldwide, with the ARCHITECT STAT
troponin I assay being used in more than 50 acute hospitals in
the UK alone. One of the main strengths of our study is that we
included all consecutive patients self presenting or referred by
their general practitioner to the emergency department, in
contrast to many clinical studies evaluating sensitive troponin
assays that recruit a highly selected group of patients
participating in international multicentre randomised controlled
trials. We therefore believe that our findings have implications
for many disciplines in clinical practice and are more
generalisable to the broad group of patients presenting with
suspected cardiac chest pain to most acute secondary and tertiary
care centres.
Limitations
Our study has some potential limitations. Firstly, these
observations are derived from a retrospective analysis from a
single tertiary cardiac centre and need to be replicated in
prospective studies including patients assessed in different
healthcare settings. Secondly, as patients with troponin
concentrations 0.012-0.049 µg/L were considered to have a
“normal” troponin concentration by the clinician responsible
for their care, the troponin test was not repeated in most patients.
We are therefore unable to determine whether raised troponin
concentration in these complex patients with previous ischaemic
heart disease was caused by dynamic release of troponin in the
context of plaque rupture, myocardial ischaemia, and infarction,
or whether it reflects cardiomyocyte apoptosis in patients with
ischaemic cardiomyopathy.27Thirdly, while we excluded patients
with clear non-cardiac causes of chest pain and renal function
was similar in patients with troponin concentrations 0.012-0.049
µg/L and ≥0.050 µg/L, it remains possible that myocardial
ischaemia in some patients will be secondary to non-cardiac
illness. The true impact of lowering the diagnostic threshold to
the 99th centile on the incidence of myocardial infarction and
on clinical outcomes will be determined only through a
prospective controlled trial.
Conclusions
In patients with suspected acute coronary syndrome, any
increase in troponin concentration above the 99th centile predicts
recurrent myocardial infarction and death. Accepting greater
assay imprecision to permit lowering the diagnostic threshold
will identify patients at high risk of recurrent events. Prospective
trials are necessary to establish whether treatment for myocardial
infarction in these patients will reduce risk and improve clinical
outcomes.
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Tables
Table 1| Baseline characteristics of all patients with suspected acute coronary syndrome stratified by peak troponin concentration. Figures
are numbers (percentage) of patients unless stated otherwise
Post hoc analysis P values
P value*
Peak troponin concentration (µg/L)
0.012-0.049 v
≥0.050
<0.012 v
≥0.050
<0.012 v
0.012-0.049≥0.050 (n=752)
0.012-0.049
(n=352)<0.012 (n=988)All (n=2092)
>0.05<0.001<0.001<0.00168 (14)70 (14)60 (14)65 (15)Mean (SD) age
(years)
0.429<0.0010.0710.002461 (61)207 (59)524 (53)1192 (57)Men
Medical history:
<0.0010.333<0.001<0.001398 (55)264 (75)499 (51)1161 (55)Previous IHD
0.0080.8110.0030.006158 (19)100 (28)202 (20)460 (22)Previous
revascularisation
0.5760.0310.0150.01966 (9)35 (10)59 (6)160 (8)Previous stroke
———0.06054 (7)17 (5)46 (5)117 (6)Peripheral vascular
disease
Risk factors:
<0.0010.321<0.001<0.001245 (33)67 (19)299 (30)611 (29)Current smoker
0.0150.8550.0190.028145 (19)91 (26)195 (20)430 (21)Ex-smoker
———0.096362 (48)194 (55)494 (50)1051 (50)Non-smoker
0.267<0.001<0.001<0.001308 (42)157 (45)326 (33)791 (38)Hypertension
<0.0010.332<0.001<0.001357 (47)218 (62)445 (45)1020 (49)Hyperlipidaemia
<0.0010.058<0.001<0.001142 (19)39 (11)224 (23)405 (19)Family history
0.5650.0020.0810.006146 (19)63 (18)137 (14)346 (17)Diabetes mellitus
Mean (SD) values on biochemistry:
<0.01<0.01<0.001<0.001134 (20)130 (17)137 (17)134 (18)Haemoglobin (g/L)
>0.05<0.001<0.001<0.00169 (26)68 (26)81 (23)75 (25)Estimated GFR
<0.01>0.05<0.001<0.0014.8 (1.3)4.5 (1.5)4.9 (1.2)4.8 (1.3)Cholesterol (mmol/L)
Electrocardiographic changes:
<0.001<0.001<0.001<0.001177 (24)49 (14)70 (8)296 (14)ST depression
<0.001<0.0011.000<0.001231 (31)3 (1)10 (1)244 (12)ST elevation
0.0050.7240.0080.00899 (15)70 (20)136 (14)305 (15)T wave inversion
0.002<0.001<0.001<0.00189 (12)67 (19)63 (6)219 (10)Bundle branch block
>0.05<0.001<0.001<0.0013.3 (1.4)3.5 (1.2)1.7 (1.4)2.4 (1.5)Mean (SD) TIMI risk
score
Drugs on admission:
0.0030.191<0.001<0.001382 (51)213 (61)470 (48)1065 (51)Aspirin
———0.05676 (10)53 (15)113 (11)242 (12)Clopidogrel
0.0041.0000.0030.005234 (31)141 (40)307 (31)682 (33)ß blockers
0.0050.007<0.001<0.001277 (37)162 (46)302 (31)741 (35)ACE inhibitors
<0.0010.663<0.001<0.001365 (49)220 (63)469 (48)1054 (50)Statins
IHD=ischaemic heart disease; GFR=glomerular filtration rate; TIMI=thrombolysis in myocardial infarction; ACE=angiotensin converting enzyme.
*Comparisons between groups of patients performed with analysis of variance for continuous variables with Tukey’s multiple comparison test between groups and
χ2 test for categorical variables with Bonferroni correction to account for multiple comparisons in post hoc analysis (P<0.0167 indicates significance).
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Table 2| Inpatient management of patients with suspected acute coronary syndrome stratified by peak troponin concentration. Figures are
numbers (percentages)
Post hoc analysis P value
P value*
Peak troponin concentration (µg/L)
0.012-0.049 v
≥0.050<0.012 v ≥0.050
<0.012 v
0.012-0.049≥0.050 (n=752)
0.012-0.049
(n=352)<0.012 (n=988)All (n=2092)
<0.001<0.0010.002<0.001692 (92)98 (28)195 (20)985 (47)Diagnosis of ACS
<0.001<0.0010.074<0.001642 (85)129 (37)310 (31)1081 (52)Cardiology
referral
<0.001<0.0011.000<0.001476 (63)22 (6)61 (6)559 (27)Coronary
angiography
<0.001<0.0010.086<0.001363 (48)14 (4)22 (2)399 (19)PCI
<0.001<0.0010.656<0.00131 (4)2 (0.7)4 (0.4)37 (2)CABG
Drugs on discharge:
<0.001<0.001<0.001<0.001667 (89)232 (66)520 (53)1419 (68)Aspirin
<0.001<0.0010.001<0.001589 (78)74 (21)133 (13)796 (38)Clopidogrel
<0.001<0.0010.030<0.001550 (73)46 (13)88 (9)684 (33)Dual
antiplatelets
<0.001<0.0010.001<0.001470 (63)149 (42)322 (32)941 (45)ß blockers
<0.001<0.001<0.001<0.001528 (70)165 (47)298 (30)991 (47)ACE inhibitors
<0.001<0.001<0.001<0.001637 (85)246 (70)497 (50)1380 (66)Statins
ACS=acute coronary syndrome; PCI=percutaneous coronary intervention; CABG=coronary artery bypass grafting; ACE=angiotensin converting enzyme,
IHD=ischaemic heart disease.
*Variables analysed with χ2 test with post hoc Fisher’s exact testing between individual groups with significance set at P<0.0167 to account for multiple comparisons.
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Table 3| Clinical outcomes in patients with suspected acute coronary syndrome stratified by peak troponin concentration below diagnostic
threshold. Figures are numbers (percentages) of patients*
Odds ratio (95% CI)P value
Peak troponin concentration
0.012-0.049 (n=352)<0.012 (n=988)All (n=1340)
3 months
6.4 (2.2 to 18.5)<0.00111 (3.1)5 (0.5)16 (1.2)Death
4.3 (1.8 to 10.7)<0.00112 (3.4)8 (0.8)20 (1.5)Myocardial infarction
4.6 (2.5 to 8.5)<0.00119 (5.4)13 (1.3)32 (2.3)Death/myocardial infarction
12 months
7.4 (3.8 to 14.2)<0.00126 (7.4)17 (1.7)43 (3.2)Death
5.2 (2.8 to 9.5)<0.00129 (8.2)17 (1.7)46 (3.4)Myocardial infarction
4.7 (2.9 to 7.9)†<0.00147 (13.4)31 (3.1)78 (5.8)Death/myocardial infarction
*Complete case analysis performed with 95 patients excluded from analysis because of missing data for covariates.
†2.6 (1.5 to 4.4) adjusted for age, sex, history of vascular disease; 2.5 (1.5 to 4.3) additionally adjusted for diabetes mellitus, hypertension, and hyperlipidaemia.
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Figures
Fig 1 Survival free from death or recurrent myocardial infarction in patients with suspected acute coronary syndrome
stratified by plasma troponin concentration
Fig 2 Association between plasma troponin concentration and odds of death or recurrent myocardial infarction. Estimates
obtained from generalised additive model with cubic smoothing spline (df=3, P=0.005 for non-linearity). Rug plot shows
density of data for given value of troponin
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Fig 3 Odds of death or recurrent myocardial infarction in patients stratified by plasma troponin concentration
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